跳转至内容
Merck

SML2561

Sigma-Aldrich

ML162

≥98% (HPLC)

别名:

α-[(2-氯乙酰基)(3-氯-4-甲氧基苯基)氨基]-N-(2-苯乙基)-2-噻吩乙酰胺, 2-氯-N-(3-氯-4-甲氧基苯基)-N-(2-氧代-2-(苯乙基氨基)-1-(噻吩-2-基)乙基)乙酰胺, BRD-5421, BRD5421, CID 3689413, ML 162, ML-162, 分子库162

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C23H22Cl2N2O3S
分子量:
477.40
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to very dark brown

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

[s]1c(ccc1)C(N(c3cc(c(cc3)OC)Cl)C(=O)CCl)C(=O)NCCc2ccccc2

InChI

1S/C23H22Cl2N2O3S/c1-30-19-10-9-17(14-18(19)25)27(21(28)15-24)22(20-8-5-13-31-20)23(29)26-12-11-16-6-3-2-4-7-16/h2-10,13-14,22H,11-12,15H2,1H3,(H,26,29)

InChI 密鑰

UNVKYJSNMVDZJE-UHFFFAOYSA-N

生化/生理作用

ML162是一种小分子,可通过共价抑制细胞磷脂谷胱甘肽过氧化物酶(GPx-4;GPx4;GSHPx-4;PHGPx;SNGPx;snPHGPx)诱导铁死亡。癌症培养物中的合成致死性研究确定了诸如HRas(G12V)表达和富马酸水合酶(FH)缺失对ML162敏感性的影响因子(在BJeLR-HRas(G12V)&UOK262-FH-/-培养物中IC50分别为25 nM & 35 nM)。
共价磷脂谷胱甘肽过氧化物酶(GPx4;GSHPx-4;PHGPx;SNGPx;snPHGPx)抑制剂,可诱导铁死亡。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Michel Weïwer et al.
Bioorganic & medicinal chemistry letters, 22(4), 1822-1826 (2012-02-03)
Synthetic lethal screening is a chemical biology approach to identify small molecules that selectively kill oncogene-expressing cell lines with the goal of identifying pathways that provide specific targets against cancer cells. We performed a high-throughput screen of 303,282 compounds from
Emilie Logie et al.
International journal of molecular sciences, 22(22) (2021-11-28)
Disease relapse and therapy resistance remain key challenges in treating multiple myeloma. Underlying (epi-)mutational events can promote myelomagenesis and contribute to multi-drug and apoptosis resistance. Therefore, compounds inducing ferroptosis, a form of iron and lipid peroxidation-regulated cell death, are appealing
Amrita Basu et al.
Cell, 154(5), 1151-1161 (2013-09-03)
The high rate of clinical response to protein-kinase-targeting drugs matched to cancer patients with specific genomic alterations has prompted efforts to use cancer cell line (CCL) profiling to identify additional biomarkers of small-molecule sensitivities. We have quantitatively measured the sensitivity
Vasanthi S Viswanathan et al.
Nature, 547(7664), 453-457 (2017-07-06)
Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple
Kenichi Shimada et al.
Cell chemical biology, 23(2), 225-235 (2016-02-09)
Precision medicine in oncology requires not only identification of cancer-associated mutations but also effective drugs for each cancer genotype, which is still a largely unsolved problem. One approach for the latter challenge has been large-scale testing of small molecules in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门